ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Watch our Breaking Science interview from ESMO Sarcoma and Rare Cancers 2026 with Georgios E. Evangelou, discussing Abstract 279MO: Durable Immune-Mediated Survival Plateau in Metastatic LCNEC After Fixed-Duration Chemo-Immunotherapy: Final 4-Year Analysis of the Prospective LANCE Study.”
Proceed to the video attached to the post.
More posts about ESMO.